Beacon Sciences: Commercialisation from biothreat detection to beauty enhancement
PDF

Keywords

chemiluminescence
supramolecular chemistry
chemosensor
synthetic receptors

Abstract

Beacon Sciences is an excellent example of how technology from an American university can be developed and commercialised resulting in applications across multiple industries and a spin-out company utilising the technology in totally new directions for the global marketplace. The pioneering work of renowned scientist, Dr Eric V. Anslyn, has led to new discoveries in the field of chemiluminescence. Financing from a life sciences venture firm, Emergent Technologies, Inc. (ETI), in an agreement with the University of Texas at Austin where the intellectual property was developed, led to the launch of Beacon Sciences and the commercialisation of the company's proprietary ‘glow chemistry’ technology and dye synthesis. The technology has wide-ranging applications, including medical diagnostics, biowarfare detection, molecular tools, environmental monitoring, food and beverage testing, chronic disease monitoring and pre-clinical drug safety testing. Funding and strong technology commercialisation management expertise provided by ETI has already led to Beacon Sciences spawning a spin-out company, Reveal Sciences, which is capitalising on Beacon Sciences technology in innovative applications for the cosmetics and personal care products industries.

https://doi.org/10.5912/jcb306
PDF

Unless specified by prior arrangement, the author agrees to the following terms and assurances:

  1. For myself and on behalf of the other authors listed on this work, I assign to thinkBiotech LLC the copyright* in the contribution for the full term throughout the world.
  2. I/we further give to the following assurances
    1. I am the sole author of the contribution, or, if not, I have the written authority of the other authors to transfer the copyright* to thinkBiotech LLC and give these warranties;
    2. I and (where appropriate) the other authors are entitled to transfer the copyright to thinkBiotech LLC and no one else would be entitled to prevent us from publishing the contribution;
    3. To the best of my/our knowledge, all the facts in the contribution are true and accurate;
    4. The content of the contribution is entirely original to me (and where appropriate to the other authors) or, if not, the written permission of the owner of the copyright in any material copied from elsewhere has been obtained for all media (all such permissions to be attached to the contribution as supplementary files);
    5. Nothing in the contribution is obscene or libellous;
    6. Nothing in the contribution infringes any duty of confidentiality which I/or the other authors may owe to anyone else.
    7. I and/or the other authors have obtained the appropriate clearances from my/our employer(s) or other concerned institution(s).
* Works by US government employees prepared as part of official duties are in the public domain and the authors are therefore exempt from copyright assignment.